Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 15;4(4):549-551.
doi: 10.1016/j.jaccao.2022.09.001. eCollection 2022 Nov.

Melanoma Treatment: The Heart Has Skin in the Game

Adolfo G Mauro  1 , Victor Yazbeck  2 , Fadi N Salloum  1   2
Affiliations
Editorial

Melanoma Treatment: The Heart Has Skin in the Game

Adolfo G Mauro et al. JACC CardioOncol. .
No abstract available

Keywords: cardiotoxicity; echocardiography; human cardiac organoids; trametinib.

PubMed Disclaimer

Conflict of interest statement

Dr Mauro is supported by National Institutes of Health (NIH) grant T32HL149645. Dr Salloum is funded by NIH grant R35HL155651. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jaccao.2022.07.009

References

    1. Indini A., Brecht I., Del Vecchio M., Sultan I., Signoroni S., Ferrari A. Cutaneous melanoma in adolescents and young adults. Pediatr Blood Cancer. 2018;65(11) doi: 10.1002/pbc.27292. - DOI - PubMed
    1. Scott J.F., Conic R.Z., Thompson C.L., Gerstenblith M.R., Bordeaux J.S., Cleveland M. Stage IV melanoma of unknown primary: a population-based study in the United States from 1973 to 2014. J Am Acad Dermatol. 2018;79(2):258–265.e4. doi: 10.1016/j.jaad.2018.03.021. - DOI - PMC - PubMed
    1. Long G.V., Stroyakovskiy D., Gogas H., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. doi: 10.1016/S0140-6736(15)60898-4. - DOI - PubMed
    1. Larkin J., Ascierto P.A., Dréno B., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876. doi: 10.1056/NEJMOA1408868. - DOI - PubMed
    1. Long G.V., Stroyakovskiy D., Gogas H., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. doi: 10.1056/NEJMOA1406037. - DOI - PubMed

Publication types